INAHTA Board Director 2022 – 2024
As a health economist, I have a passion for the multi-disciplinary questions that are at the core of health technology assessment, with its interlinkage of aspects relating to medicine, economics, ethics, and practical decision-making. In my experience, the health economic viewpoint is highly suited to bringing together data and evidence from different perspectives and sources, with the goal to provide the best possible basis for decision-making.
I have about 20 years of experience from government HTA agencies, consulting, and academic research (with a PhD in Health economics and epidemiology). I appreciate the value of international exchange, having lived in Germany, the UK, and Sweden. During my career, I have contributed to and lead cross-functional projects and teams from different countries, involving a wide range of different health economic research questions and methodologies.
I believe there is a need for continued development of international collaboration from an HTA perspective around health economic questions. INAHTA provides a unique organizational platform for this through its network of government-funded agencies. I think there is a role for best practice to advance the science and policy impact of HTA, which will be required considering the rapid development of medical science and continued challenges to healthcare systems and budgets. There is a need for the voice of HTA agencies to also be heard in the field of health economics, and I think that INAHTA has the potential to be that voice.
I am eager to contribute to the progression of processes and methods in the field of HTA and health economics on an international level. I am enthusiastic about the opportunities for international collaboration that are possible with INAHTA and feel very honoured to join the INAHTA Board of Directors.